
Progress at last against RSV
The approval of two vaccines and a monoclonal antibody that target respiratory syncytial virus could shift the tide on the prevention and treatment of infection with this virus.
The approval of two vaccines and a monoclonal antibody that target respiratory syncytial virus could shift the tide on the prevention and treatment of infection with this virus.
Mounting evidence, including the recent (and unprecedented) phase 2 data on retatrutide, supports a role for incretin hormone agonists in treating obesity. But with great power comes great responsibility.